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The DNA mismatch repair gene is a key regulator in the elimination of base–base mismatches and insertion/deletion loops (IDLs).
Human MutS homologue 2 (hMSH2), originally identified as a human homologue of the bacterial MutS, is a tumour suppressor gene
frequently mutated in hereditary nonpolyposis colorectal cancer. Hereditary nonpolyposis colorectal cancer is characterised by the
early onset of colorectal cancer and the development of extracolonic cancers such as endometrial, ovarian, and urological cancers.
Oestrogen receptor (ER) a and b are members of a nuclear receptor (NR) superfamily. Ligand-dependent transcription of ER is
regulated by the p160 steroid receptor coactivator family, the thyroid hormone receptor-associated proteins/the vitamin D receptor-
interacting proteins (TRAP/DRIP) mediator complex, and the TATA box-binding protein (TBP)-free TBP associated factor complex
(TFTC) type histone acetyltransferase complex. Here, we report the interaction between ER a/b and hMSH2. Immunoprecipitation
and glutathione-S-transferase pulldown assay revealed that ER a and hMSH2 interacted in a ligand-dependent manner, whereas ER b
and hMSH2 interacted in a ligand-independent manner. Oestrogen receptor a/b bound to hMSH2 through the hMSH3/hMSH6
interaction domain of hMSH2. In a transient expression assay, hMSH2 potentiated the transactivation function of liganded ER a, but
not that of ER b. These results suggest that hMSH2 may play an important role as a putative coactivator in ER a dependent gene
expression.
British Journal of Cancer (2005) 92, 2286–2291. doi:10.1038/sj.bjc.6602614 www.bjcancer.com
Published online 10 May 2005
& 2005 Cancer Research UK
Keywords: hMSH2; HNPCC; ER a;E Rb; coactivator; transactivation
                                                     
The mismatch repair (MMR) system was originally identified in
bacteria, and its inactivation results in an increase in the rate of
spontaneous mutations owing to the inability to repair the
replication errors. The best understood function of the MMR
system is to eliminate single-base mismatches and insertion–
deletion loops (IDLs) that may arise during DNA replication by
DNA polymerases (Glickman and Radman, 1980; Modrich, 1997).
In the first step of the repair process in humans, DNA mismatches
are efficiently recognised by protein heterodimers containing
human MutS homologue 2 (hMSH2). The most abundant complex
is hMutSa, a heterodimer containing hMSH2 and hMSH6. The
quantitatively more minor recognition factor hMutSb is a
heterodimer comprising hMSH2 and hMSH3. The subsequent step
of repair involves hMutLa, a heterodimer comprising human MutL
homologue 1 (hMLH1) and hPMS2, which interacts with hMutSa,
and directs the removal and replacement of a long stretch of DNA
containing the mismatches or IDLs (Ban et al, 1999). The functions
of hMSH3 and hMSH6 are thought to be not critical for the repair
of DNA mismatches because the disruption of either hMSH3 or
hMSH6 leads to a mild mutator phenotype (Marsischky et al,
1996). In contrast, hMSH2 is indispensable to the recognition of
mismatches and the inactivation of hMSH2 is responsible for a
phenotype referred to as replication error or microsatellite
instability (Bubb et al, 1996).
Hereditary nonpolyposis colorectal cancer (HNPCC) acounts for
approximately 2–5% of all colorectal cancer (Mitchell et al, 2001),
and remains the most common of the recognised inherited
colorectal cancer syndrome. Hereditary nonpolyposis colorectal
cancer is predisposed to the early onset of colorectal cancer and
the development of extracolonic neoplasms including endometrial,
ovarian, urological, and upper gastrointestinal cancers (Rodriguez-
Bigas et al, 1996). The identification of MMR gene mutations
associated with HNPCC revealed a novel mechanism of cancer
pathogenesis (Fishel et al, 1993; Leach et al, 1993). Hereditary
nonpolyposis colorectal cancer is associated with germ-line
mutations of the MMR genes, most commonly hMSH2 and
hMLH1. The hMSH2 gene, located on chromosome 2p22–p2,
consists of 15 exons and encodes a relatively large protein of 934
amino acids. The mutations of hMSH2 represent approximately
40% of the mutations detected in HNPCC kindreds. Among the 154
different hMSH2 mutations that have been analysed approximately
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s80% of the hMSH2 mutations lead to premature termination of the
hMSH2 gene product. The truncated hMSH2 gene product may
lose its critical functions (Drotschmann et al, 1999), which is
related to the development of HNPCC.
Oestrogen receptor is a member of the nuclear hormone
receptor gene superfamily and acts as a ligand-induced transcrip-
tion factor (Mangelsdorf et al, 1995). Oestrogen receptor is
stimulated by two distinct activation regions, activation function-
1 (AF-1) and AF-2. Activation function-1, which is located in the
N-terminal A/B domain, is constitutively activated in cell-type and
promoter-specific manner (Metzger et al, 1995). Activation
function-2 is located in the C-terminal ligand-binding domain
and exerts a ligand-dependent transcriptional activation. Activa-
tion function-1 and AF-2 activate transcription independently and
act synergistically (Lopez et al, 1999). Oestrogen receptor a contact
the general transcription factors either directly or indirectly via
coactivator proteins, including AF-1 coactivator p300 (Kobayashi
et al, 2000) and p68/p72 (DEAD box protein) (Watanabe et al,
2001). The ligand-dependent activation of ER a requires ligand-
dependent association of AF-2 coactivator complex, including
p300/CBP, pCAF, the p160 family members SRC-1/TIF-2/pCIP/
AIB-1/GRIP1/ACTR (McKenna et al, 1999), the thyroid hormone
receptor-associated proteins/the vitamin D receptor-interacting
proteins (TRAP/DRIP) (Rachez et al, 2000; Kang et al, 2002), the
transformation/transcription domain-associated protein (TRRAP),
and the histone acetyltransferase GCN5 (Yanagisawa et al, 2002).
We have recently revealed that breast cancer susceptibility gene
1 (BRCA1), hMSH2, and GCN5 formed a complex to work on DNA
repair (unpublished data). Current studies have implicated DNA
repair proteins, including the T:G mismatch specific thymine DNA
glycosylase (Chen et al, 2003), and the xeroderma pigmentosum
complementary group D (XPD) (Keriel et al, 2002) in the
transcription regulation by nuclear receptors (NRs). On the basis
of the report showing the transcriptional squelching between
BRCA1 and ER a (Fan et al, 1999), we investigated the functional
interaction between hMSH2 and ER a.
MATERIALS AND METHODS
Cell culture
Oestrogen receptor a/b-positive T-47D (HTB-133) and ER b-
positive MDA-MB-231 (HTB-26) human breast cancer cell lines
were purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Oestrogen receptor a-positive
Ishikawa human endometrial cancer cell line was kindly provided
by Dr M Nishida (Tsukuba University, Tsukuba, Japan), and
hMSH2-deficient HEC59 human endometrial cancer cell line was a
generous gift from Dr H Kuramoto (Kitasato University,
Sagamihara, Japan). These cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Sigma Aldrich, St Louis, MO,
USA) supplemented with 10% fetal bovine serum (Sigma Aldrich).
Immunoprecipitation
Formation of ER a–hMSH2 complex in Ishikawa cells and ER b–
hMSH2, BRCA1–hMSH2 (Wang et al, 2001) complex in MDA-MB-
231cells were analysed by co-immunoprecipitation using the
specific antibody raised against human ER a (G-20), human ER
b (H-150), and human BRCA1 (C-20), followed by immunoblotting
using the anti-hMSH2 antibody (N-20). All the antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The 310
6 cells were suspended in 1000ml of TNE buffer (10mM
Tris-HCl (pH 7.8), 1% Nonidet-P40, 0.15 M NaCl, 1mM EDTA, 1mM
phenylmethylsulphonyl fluoride, and 1mgml
1 aprotinin). The
cells were disrupted by repeated aspiration through 27-gauge
needle and cellular debris were precipitated by centrifugation at
12000r.p.m. for 30min at 41C. The whole supernatant was applied
for immunoprecipitation with 3mg of the antibodies to ER a,E Rb,
BRCA1, or IgG. Then, 30ml of protein G sepharose
TM 4 Fast Flow
(Amersham Biosciences, Buckinghamshire, UK) was added, and
subsequently the bound proteins were purified as a protein
complex. After washing with TNE buffer four times, the interacting
proteins were separated by 7.5% SDS–polyacrylamide gel electro-
phoresis, transferred onto Hybond
TM-ECL
TM nitrocellulose mem-
brane (Amersham Biosciences), and detected by Western blotting
with the anti-hMSH2 antibody. ECL detection was performed
according to the manufacturer’s recommendations.
Plasmid construction
TRAP220 and SRC-1 expression vectors were described previously
(Fujita et al, 2003; Wada et al, 2004). Human MutS homologue 2
expression vector was constructed from human testis library
(Clontech, Palo Alto, CA, USA). Fragments of hMSH2 were
inserted into pcDNA FLAG vector derived from pcDNA 3
(Invitrogen, Carlsbad, CA, USA). Human ERa AF-1 (1–180), ER
a AF-2 (263–595), ER b AF-1 (1–149), and ER b AF-2 (248–530)
vectors were described previously (Fujita et al, 2003). Reporter
constructs (17M8 b globin-luc) have been described previously
(Wada et al, 2004).
Glutathione-S-transferase-pulldown assay
Glutathione-S-transferase (GST) fusion proteins or GST alone were
expressed in Escherichia coli and bound to glutathione-sepharose
4B beads (Amersham Biosciences). Immobilised GST-ER a/b AF-1
or AF-2 fusion proteins were preincubated for 30min in NET
buffer (20mM Tris-HCl pH 7.5, 200mM NaCl, 1mM EDTA) with or
without 17-b estradiol (106 M). The GST proteins were incubated
at 41C with [
35S]methionine (Amersham Biosciences)-labeled
proteins expressed by in vitro translation using the TNT-coupled
transcription–translation system (Promega Co., Madison, WI,
USA). After 1h incubation, unbound proteins were removed by
washing the beads three times in NET buffer with 0.5% Nonidet P-
40 and 1mM phenylmethylsulphonyl fluoride. Specifically bound
proteins were eluted by boiling in SDS sample buffer and analysed
by 7.5–15% SDS–polyacrylamide gel electrophoresis and auto-
radiography. Polyacrylamide gels were stained briefly with
Coomassie Brilliant Blue to verify the loading of equal amounts
of fusion proteins prior to drying and autoradiography.
Luciferase assay
At 2 days before transfection, the medium was changed to phenol
red-free DMEM containing 5% charcoal stripped fetal bovine
serum. Transfection was performed with PolyFect reagent (Quia-
gen, Inc., Chartsworth, CA, USA) according to the manufacturer’s
recommendations. For luciferase assay, 250ng 17M8 b-globin-luc
plasmid was cotransfected with 250ngpM ER a AF-2 or pM ER b
AF-2. Indicated expression vectors were also cotransfected with ER
vectors. As an internal control to equalise transfection efficiency,
5ng pRL CMV vector (Promega Co., Madison, WI, USA) was
cotransfected in all the experiments. Individual transfections, each
consisting of triplicate wells, were repeated at least three times
(Wada et al, 2004).
RESULTS
ER a/b and hMSH2 interacts in vivo
To determine whether endogenous hMSH2 protein interacted with
ER a,E Rb, and BRCA1 in the cultured human cells, we performed
immunoprecipitation assays by using the antibodies raised against
ER a,E Rb, and BRCA1. Oestrogen receptor a was immunopre-
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scipitated in Ishikawa cell lysate. Oestrogen receptor b and BRCA1
were immunoprecipitated in MDA-MB-231 cell lysate. Complex
formation of the precipitated proteins was confirmed by Western
blotting. Immunoblotting revealed the exsistence of hMSH2 in the
cell lysate immunoprecipitates (Figure 1A(i)), which supports our
hypothesis that hMSH2 physically associates with ER a and ER b in
living cells. These results were further confirmed by reciprocal
immunoprecipitation with the specific antibody raised against
hMSH2. Immunoblotting again revealed the exsistence of ER a and
ER b (Figure 1A(ii)).
ER a and hMSH2 interact in vitro in a ligand-dependent
manner, and ER b and hMSH2 interact in vitro in a ligand-
independent manner
To address the functional importance of the hMSH2-ER a and
hMSH2-ER b interaction, in vitro translated hMSH2 in the
presence of [
35S] methionine was incubated with GST-fused ER
a/b AF-1 or ER a/b AF-2. As clearly shown in Figure 1B, the
liganded GST-fused ER a AF-2 protein possessed the ability to
retain hMSH2 on the column. On the other hand, GST-fused ER a
AF-2 protein without the ligand, and GST-fused ER a AF-1 protein
lacked the ability to retain hMSH2 on the column. Liganded ER a
AF-2 possessed the ability to retain TRAP220, one of the
coactivator of ER a. These data indicated that hMSH2 directly
interacts with ER a AF-2 in a ligand-dependent manner, similar to
TRAP220. Glutathione-S-transferase-fused ER b AF-2 protein
possessed the ability to retain hMSH2 on the column regardless
of the presence of ligand (Figure 1B). Glutathione-S-transferase-
fused ER b AF-1 protein lacked the ability to retain hMSH2 on the
column. These results indicated that hMSH2 directly interacts with
ER b AF-2 in a ligand-independent manner.
Mapping of the region of hMSH2 that interacts with ER a
AF-2 and ER b AF-2
To map the region of hMSH2 that interacted with ER a/b AF-2, a
GST pulldown assay was performed using GST-fused ER a/b AF-2,
and in vitro translated hMSH2 fragments (Figure 2). The FLAG-
tagged hMSH2 fragments, abbreviated ‘F1’ (1–178), ‘F2’ (179–
377), ‘F3’ (378–625), ‘F4’ (609–888), and ‘F5’ (793–934), were in
vitro translated and tested for the interaction with ER a/b. Only F3
region of hMSH2 interacted with ER a AF-2 in a ligand-dependent
manner. Thus, F3 of hMSH2 complexed with ER a via the hMSH3/
hMSH6 interaction domain. Interestingly, the liganded ER a
column did not retain F2, which contains LXXLL motifs thought to
interact with liganded NRs (Heery et al, 1997; Voegel et al, 1998).
F3 and F4 regions of hMSH2 interacted with ER b AF-2 in a ligand-
independent manner. Thus, F3 and F4 of hMSH2 complexed with
ER b via the hMSH3/hMSH6 interaction domain.
hMSH2 potentiates the transactivation function of ER a in
a ligand-dependent manner
To examine the coactivator activity of hMSH2 in the transactiva-
tion function of ER a/b, a transient transfection assay was
performed using a luciferase reporter plasmid driven by the b-
globin promoter containing GAL4 DNA-binding domain. While
ER a-GAL4 fusion protein (GAL-ER a AF-2) showed a ligand-
dependent transactivation function in human HEC59 endometrial
cancer cells, a transient coexpression of hMSH2 led to an
approximately 2.5-fold increase in the luciferase activity compared
to that of GAL-ER a AF-2 alone (Figure 3). The promoted
transactivation function by hMSH2 was comparable to that by AF-
2 coactivators, SRC-1 and TRAP220. This enhancement of
transactivation by hMSH2 was observed in hMSH2-deficient
HEC59 cells, but not in the other cell lines, MDA-MB-231 and T-
47D (data not shown). The ligand-induced transactivation was not
promoted by hMSH2 when GAL-ER b AF-2 was used (Figure 3), as
expected from the in vitro ER a/b experiments. This again
suggested a significant role of hMSH2 in the ligand-dependent
transactivation function of ER a.
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Figure 1 In vivo association between hMSH2 and ER a/b and in vitro
association between hMSH2 and ER a/b. (A) (i) Ishikawa cells were lysed
and subjected to immunoprecipitation (IP) with the antbodies to ER a and
IgG. MDA-MB-231 cell lysate was immunoprecipitated with the antbodies
to ERb BRCA1 and IgG. The immunoprecipitates were separated by SDS–
PAGE and analysed by immunoblotting (IB) with the anti-hMSH2 antibody.
(ii) Reciprocal IP was performed to detect endogenous hMSH2-ER a and
hMSH2-ER b interactions by IB. (B) In vitro translated
35S-labelled hMSH2
was pulled down by GST-ER a/b AF-1 or GST-ER a/b AF-2. At the same
time, in vitro translated TRAP220 was incubated with GST-ER a AF-2. The
mixtures were washed and subjected to SDS–PAGE and analysed.
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sDISCUSSION
We showed that endogenous ER a/b associated with wild-type
hMSH2 in the cultured human cells. Immunoblotting revealed the
exsistence of hMSH2 in the cell lysate immunoprecipitates, which
was confirmed by reciprocal immunoprecipitation with the
specific antibody raised against hMSH2. The direct interaction
between ER a/b and hMSH2 was investigated by GST pulldown
assays. The GST-fused ER a AF-2 protein showed the ability to
retain hMSH2 in a ligand-dependent manner. F3 region of hMSH2
interacted with ER a AF-2 in a ligand-dependent manner, which
was supported by the findings that ER a alone potently enhanced
hMSH2 transactivation function. In contrast, F3 and F4 regions of
hMSH2 interacted with ER b AF-2 in a ligand-independent
manner, and ER b lacked the ability to enhance hMSH2
transactivation function. These results indicated that the ER a/b-
containing complexes might play a role in the MMR system of
hMSH2.
Ligand-dependent interaction of hMSH2 was identified as a
unique property because hMSH2 directly binds to ER a AF-2 as if
hMSH2 acts as an ER coactivator. Although hMSH2 has three NR
recognition motifs (LXXLL, NR box), these motifs have no
significant role in the binding of ER a and ER b. Given that
hMSH2 may promote gene regulation with ERs, and that the
mutations in hMSH2 may lead to an altered ER a-dependent gene
regulation and an altered tumorigenesis in oestrogen-dependent
cancers (presumably through the modulation of ER-mediated
oestrogen signalling), the interaction between ER a/b and hMSH2
may partially account for the relationship between HNPCC and
oestrogen-dependent extracolonic tumours such as endometrial
cancer. Our results also indicated that hMSH2 competed with ER a
in terms of transcriptional control via the hMSH3/hMSH6
interaction domain of hMSH2, which suggestes the possibility
that the common coactivator complexes of ER, including the p160
family complex, TRAP/DRIP complex and TFTC complex, might
have a functional relationship with the MMR complex.
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Figure 2 Mapping of the ER a/b-interacting region of hMSH2. A schematic diagram of the structure of hMSH2 is shown. ‘F1’, ‘F2’, ‘F3’, ‘F4’, and ‘F5’
fragments of hMSH2 were in vitro translated. In view of the result of Figure 1, the fragments of hMSH2 and GST-ER a/b AF-2 were tested for detection. The
mixtures were washed and subjected to SDS–PAGE and then visualised by autoradiography.
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many of these effects result from a direct interaction of oestrogen
with an NR that activates the expression of genes encoding
proteins with important biological functions. Oestrogen has a
mitogenic action in hormone-sensitive tissues such as the uterus.
In addition to this action, oestrogen possesses carcinogenic
activity. Prolonged exposure to oestrogen without opposing by
progesterone is considered to cause endometrial hyperplasia and
endometrioid adenocarcinoma in relatively young women. The
interaction between ER a/b and hMSH2 might have a significant
role in the pathogenesis of endometrial cancer. Recently, it was
reported that not only tamoxifen, a selective oestrogen receptor
modulator (SERM) used in the treatment of breast cancer, but also
oestrogen derivatives possess a high mutagenic potential (Mizutani
et al, 2004), which is attained by two mechanisms. First, DNA
replication blocks may cause chromosomal breaks and lead to
translocation or large deletion. Second, the employment of error-
prone translesion DNA synthesis polymerases to bypass DNA
damage is likely to result in an accumulation of point mutations.
On the other hand, withdrawal of oestrogen may increase a risk of
microsatellite instability-positive colon cancer based on the
epidemiological data (Slattery et al, 2001). Considering the present
data, ER itself may have a fuctional role in DNA MMR. Especially,
ER b, which is expressed in colon cancer (Gustafsson, 2003), may
have a potent role through the ligand-independent interaction with
hMSH2.
The present study showed that ER a/b bound directly to wild-
type hMSH2. Considering the fact that most mutations found in
the patients of HNPCC result in a premature truncation of hMSH2,
the loss of hMSH3/hMSH6 interaction domain in hMSH2 may
result in a loss of interaction between ER a/b and hMSH2. In this
respect, the functional interaction between ERa/b and hMSH2 may
be required to prevent or promote the progression in the
pathogenesis of endometrial cancer complicating HNPCC. Our
transient transfection assay showed that the MMR complex clearly
served as a coactivator complex in the promoters of ER a target
genes because hMSH2 enhanced ER a-mediated ligand-dependent
transactivation function. Further investigations should be per-
formed to elucidate the molecular mechanisms that underlie the
formation of ERa/b-hMSH2 complexes in normal cell growth,
thereby revealing hMSH2 as a tumour suppressor in oestrogen-
responsive organs, especially the endometrium. In conclusion,
these results suggest that the failure of binding between hMSH2
and ER a/b may be a key event in cancer predisposition.
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